PAP
PCVX icon

Persistent Asset Partners’s Vaxcyte PCVX Stock Holding History

Persistent Asset Partners’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$323K Buy
+135
New +$7.33K 0.12% 146

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Persistent Asset Partners's PCVX Position: Q1 2026 in Review

Persistent Asset Partners reduced its Vaxcyte (PCVX) stake by 0.28% in Q1 2026, selling an estimated $814 and leaving 5,319 shares worth $309K. The position accounts for 0.12% of the portfolio, ranked #152.

Persistent Asset Partners first reported a position in PCVX in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.8M in Q3 2025. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

  • Persistent Asset Partners held 5,319 shares of Vaxcyte worth $309K as of Q1 2026.
  • Persistent Asset Partners sold 15 Vaxcyte shares in Q1 2026, an estimated $814.
  • Vaxcyte made up 0.12% of Persistent Asset Partners's portfolio in Q1 2026, its #152 holding.
  • Persistent Asset Partners first reported a position in Vaxcyte in Q4 2024 and has held it in 6 quarters since.
  • Persistent Asset Partners's Vaxcyte position peaked at $1.8M in Q3 2025.
  • 336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.